- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03143816
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study (STAT)
This is an investigator-initiated, prospective, randomized, multicenter, parallel, open-label, pilot clinical trial evaluating the efficacy of TI for PPBG, PPGE, and time-in-range on CGM download in patients with T1D. TI is an inhaled ultra-rapid-acting insulin, approved by the FDA for use in patients with diabetes. This is a pilot, real-life study where patients will continue their routine diabetes care and use post-meal correction dosages as deemed necessary for normalizing PPBG as per the protocol.
This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
All patients will use real-time CGM (Dexcom G5®, San Diego, CA), which will be provided at the randomization visit for their day-to-day diabetes care. CGM data will be downloaded at every clinic visit on a secured computer. The data will be analyzed after the study for different primary and secondary end points. All patients will be allowed to keep the CGM after the study is over for their day-to-day diabetes care.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Barbara Davis Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent before any study-related activities,
- Male or female aged 18-70 years,
- Type 1 diabetes mellitus (T1D) duration more than six months
- Treatment with multiple daily injections (MDI) for at least three months before screening visit; stable insulin dose for the last one month,
- No use of any oral anti-diabetics, any other form of insulin other than mentioned in the protocol, or any other type of injections such as glucagon-like-peptide-1 (GLP-1) analogs, pramlintide or insulin/GLP-1 analog combinations,
- A1c between 6.5 to 10%,
- Willingness to routinely collect at least two blood glucose measurements per day needed to calibrate the CGM. Beyond the calibrations, patients may use CGM for necessary action without having to confirm with fingersticks self-monitoring blood glucose (SMBG), as approved by the Food and Drug Administration (FDA),
- BMI ≤35 kg/m2,
- Ability and willingness to adhere to the protocol including clinical and phone visits and 4-week-long CGM wear,
- Using insulin glargine or insulin degludec as basal insulin,
- Able to use and understand CGM data,
- Willing to complete phone and clinic visits,
- Patients who eat three main meals in a day (breakfast, lunch, and dinner),
- Patients who use insulin-carb ratio for bolus,
- Ability to speak, read, and write English, and
- Patients prandial insulin need must be <18 units per meal
Exclusion Criteria:
- Use of any other diabetic medication other than allowed in the protocol,
- Pregnant or intention to become pregnant during the study, or not using adequate birth control methods,
- Severe unexplained hypoglycemia requiring emergency treatment in the previous three months,
- Use of systemic or inhaled corticosteroids,
- History of hemoglobinopathies,
- Diagnosis of anemia,
- Post-renal transplantation, currently undergoing dialysis, creatinine >2.0 mg/dl or a calculated creatinine clearance of <50 mL/min,
- Advanced or unstable retinopathy needing laser procedure or vitrectomy,
- History of pancreatitis,
- Extensive skin changes/diseases that inhibit wearing a sensor on normal skin,
- Known allergy to adhesives,
- Known allergy to study medication,
- Participation in another investigational study protocol within 30 days before enrollment,
- Known chronic obstructive pulmonary disease, pulmonary hypertension, asthma, pulmonary fibrosis, or any chronic pulmonary infection, or any systemic disease that primarily affects the lungs. History of any pulmonary nodule will be excluded to participate in the study,
- Active smokers,
- Marijuana users,
- Insulin pump users,
- Using insulin detemir or NPH as basal insulin, and
- Any other condition, as determined by the investigator, which could make the subject unsuitable for the trial, impairs the subject's suitability for the trial, or impairs the validity of the informed consent -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Technosphere insulin (TI, Afrezza) -Treatment arm
Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG ( post prandial blood glucose)
|
This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%.
The patients will be randomized in 1:1 fashion to either TI or NL.
Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals.
Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B).
There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits).
There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up.
(Phone visit; Figure-1).
Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
|
No Intervention: Insulin Aspart ( Novolog) -Control arm
Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Time in Range (%) (70-180 mg/dl) With TI on CGM
Time Frame: 4 weeks
|
Difference between Time in range for TI group (treatment) and for Aspart group (control)
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Post-prandial Glucose Excursion (mg/dl) (1-4 Hours After Meals) With TI
Time Frame: 4 weeks
|
Difference in postprandial blood glucose between treatment and control group
|
4 weeks
|
Change in Glucose Variability (GV) (mg/dl) (Standard Deviation and/or Coefficient Variation)
Time Frame: 4 weeks
|
Difference of glucose variability metrics between treatment and control groups
|
4 weeks
|
The Area Under the Curve Calculation (AUC) (Min*mg/dl) in the PPBG and PPGE,
Time Frame: 0, 1, 2, 3, 4 hours post-dose at 4 weeks
|
Difference of area under curve between treatment and control groups.
( 0 to 4 hours duration)
|
0, 1, 2, 3, 4 hours post-dose at 4 weeks
|
Change in HbA1c (%) in One-month Treatment
Time Frame: 4 weeks
|
Difference in HbA1c between treatment and control group
|
4 weeks
|
Change in Above the Target Time (%) (>180 mg/dl) on CGM
Time Frame: 4 weeks
|
Difference of time above range between treatment and control group
|
4 weeks
|
Hypoglycemia Frequency (%) (Below the Target <70mg/dl) on CGM
Time Frame: 4 weeks
|
Difference of hypoglycemia frequency between treatment and control groups.
|
4 weeks
|
Collaborators and Investigators
Publications and helpful links
General Publications
- 1. Rathbone M, Hadgraft J, Roberts M, Lane M, Leone-Bay A, Grant M. Technosphere/insulin: mimicking endogenous insulin release. In Modified-Release Drug Delivery Technology. Vol. 2, 2nd ed. Rathbone M, Hadgraft J, Roberts M, Lane M, Eds. New York, Informa Healthcare USA, Inc., 2008, p. 673-679
- Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S65-72. doi: 10.1089/dia.2007.0212.
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022472lbl.pdf, April 2017
- Bode BW, McGill JB, Lorber DL, Gross JL, Chang PC, Bregman DB; Affinity 1 Study Group. Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial. Diabetes Care. 2015 Dec;38(12):2266-73. doi: 10.2337/dc15-0075. Epub 2015 Jul 15.
- Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, Petrucci RE, Boss AH, Richardson PC. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010 Jun 26;375(9733):2244-53. doi: 10.1016/S0140-6736(10)60632-0.
- Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC; Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care. 2005 Jul;28(7):1630-5. doi: 10.2337/diacare.28.7.1630.
- Garg SK, Kelly W, Freson B, Ritchie P. Treat-to-target technosphere insulin study in adult subjects with type 1 diabetes. Poster presented at American Diabetes Association 2011 annual meeting.
- Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 Oct;20(10):639-647. doi: 10.1089/dia.2018.0200. Epub 2018 Sep 15.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-0427
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Technosphere insulin
-
Mannkind CorporationCompleted
-
Mannkind CorporationCompletedType 2 Diabetes Mellitus
-
Mannkind CorporationCompleted
-
Mannkind CorporationCompletedType 2 DiabetesUnited States, Russian Federation, Brazil, Ukraine
-
Mannkind CorporationCompletedHealthy VolunteersUnited States
-
Mannkind CorporationCompletedDiabetes Mellitus, Type 2United States, Brazil, Spain, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, Ukraine, Czech Republic
-
Mannkind CorporationCompleted
-
Mannkind CorporationCompletedType 1 Diabetes MellitusUnited States, Brazil, Russian Federation, Ukraine
-
Mannkind CorporationCompletedDiabetes Mellitus | Upper Respiratory InfectionUnited States, Russian Federation, Canada
-
Mannkind CorporationCompletedDiabetes Mellitus, Type 2Germany